221
Views
3
CrossRef citations to date
0
Altmetric
Perspectives

Meibomian Gland Dysfunction: A Dermatological Perspective on Pathogenesis and Treatment Outlook

, , , ORCID Icon, ORCID Icon, , , ORCID Icon & show all
Pages 4399-4404 | Published online: 09 Nov 2021

References

  • Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221–232.
  • Nichols KK. The international workshop on Meibomian gland dysfunction: introduction. Invest Ophthalmol Vis Sci. 2011;52:1917–1921. doi:10.1167/iovs.10-6997
  • Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on Meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–1929. doi:10.1167/iovs.10-6997a
  • Knop E, Ludescher M, Knop N. Keratinization status and cytokeratins of the human Meibomian gland epithelium. Acta Ophthalmol. 2009;87:2232. doi:10.1111/j.1755-3768.2009.2232.x
  • Knop E, Knop N, Millar T, et al. The international workshop on Meibomian gland dysfunction: report on the subcommittee on anatomy, physiology, and pathophysiology of the Meibomian gland. Invest Ophthalmol Vis Sci. 2011;52(4):1938–1978. doi:10.1167/iovs.10-6997c
  • Green‐Church KB, Butovich I, Willcox M, et al. The international workshop on Meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid‐protein interactions in health and disease. Invest Ophthalmol Vis Sci. 2011;52(4):1979‐93. doi:10.1167/iovs.10-6997d
  • Butovich IA. The Meibomian puzzle: combining pieces together. Prog Retin Eye Res. 2009;28(6):483–498. doi:10.1016/j.preteyeres.2009.07.002
  • Tsai PS, Evans JE, Green KM, et al. Proteomic analysis of human Meibomian gland secretions. Br J Ophthalmol. 2006;90(3):372–377. doi:10.1136/bjo.2005.080846
  • Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1(3):107–126. doi:10.1016/S1542-0124(12)70139-8
  • Deo PN, Deshmukh R. Pathophysiology of keratinization. J Oral Maxillofac Path. 2018;22(1):86–91.
  • Jester JV, Parfitt GJ, Brown DJ. Meibomian gland dysfunction: hyperkeratinization or atrophy?. BMC Ophthalmol. 2015;15(S1):3–11.
  • Ong BL, Hodson SA, Wigham T, et al. Evidence for keratin proteins in normal and abnormal human Meibomian fluids. Curr Eye Res. 1991;10(12):1113‐1119. doi:10.3109/02713689109024128
  • Obata H. Anatomy and histopathology of human Meibomian gland. Cornea. 2002;21(7 Suppl):S70‐S74.
  • Blackie CA, Korb DR, Knop E, et al. Nonobvious obstructive Meibomian gland dysfunction. Cornea. 2010;29(12):1333–1345. doi:10.1097/ICO.0b013e3181d4f366
  • Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc. 1980;51:243–251.
  • Jester JV, Nicolaides N, Smith RE. Meibomian gland dysfunction. I. Keratin protein expression in normal human and rabbit meibomian glands. Invest Ophthalmol Vis Sci. 1989;30(5):927‐935.
  • Soria J, Acera A, Durán JA, et al. The analysis of human conjunctival epithelium proteome in ocular surface diseases using impression cytology and 2D-DIGE. Exp Eye Res. 2018;167:31‐43. doi:10.1016/j.exer.2017.03.006
  • Ibrahim OM, Dogru M, Matsumoto Y, et al. Oxidative stress induced age dependent Meibomian gland dysfunction in Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice. PLoS One. 2014;9(7):e99328. doi:10.1371/journal.pone.0099328
  • Shine WE, McCulley JP. Meibomianitis: polar lipid abnormalities. Cornea. 2004;23:781–783. doi:10.1097/01.ico.0000133995.99520.1f
  • Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction (MGD). Cornea. 2012;31(4):396–404. doi:10.1097/ICO.0b013e318239aaea
  • Maskin SL, Testa WR. Growth of Meibomian gland tissue after intraductal Meibomian gland probing in patients with obstructive Meibomian gland dysfunction. Br J Ophthalmol. 2018;102(1):59–68. doi:10.1136/bjophthalmol-2016-310097
  • Babilas P, Knie U, Abels C. Cosmetic and dermatologic use of alpha hydroxy acids. J German Soc Dermatol. 2012. doi:10.1111/j.1610-0387.2012.07939.x.
  • Gupta AK, Foley KA, et al. Topical antifungal agents. In: Comprehensive Dermatologic Drug Therapy. 4th ed. 2021.
  • AHFS Drug Information. Selenium Sulfide. McEvoy GK, editor. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3521–3522.
  • Bahn GC. The treatment of seborrheic blepharitis. South Med J. 1954;47(8):749–753. doi:10.1097/00007611-195408000-00008
  • Thygeson P, Vaughan DG Jr. Seborrheic blepharitis. Trans Am Ophthalmol Soc. 1954–1955;52:173–188.
  • Cohen LB. Use of selsun in blepharitis marginalis. Am J Ophthalmol. 1954-1955;38(4):560–562. doi:10.1016/0002-9394(54)90708-4
  • Wong AS, Fasanaella RM, Haley LD, et al. Selenium (selsun) in the treatment of marginal blepharitis. AMA Arch Ophthalmol. 1956;55(2):246–253. doi:10.1001/archopht.1956.00930030250011
  • Downie LE, Watson SL, Tan JL, Stapleton F, Bosworth C. A multicenter, double-masked, vehicle-controlled, randomized, parallel group clinical trial of AZR-MD-001 (Sterile Ophthalmic Ointment Selenium Sulfide SeS2) in individuals with Meibomian gland dysfunction. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1 07; 2021. Virtual.
  • Craig J, Stapleton F, Tan J, et al. Randomized controlled trial evaluating novel keratolytic for MGD Treatment. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1 07; 2021. Virtual.
  • Stapleton F, Tan J, Jia T, DePuy V, Gleeson M, Bosworth C The effect of a novel selenium sulfide-containing topical treatment on ocular signs and symptoms in symptomatic contact lens wearers: an exploratory study. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; May 107; 2021. Virtual.